关注
Lauren Averett Byers, MD, MS
Lauren Averett Byers, MD, MS
在 mdanderson.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ...
New England Journal of Medicine 346 (25), 1937-1947, 2002
47912002
Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
Nature 511 (7511), 543, 2014
38952014
Comprehensive genomic characterization of squamous cell lung cancers
Cancer Genome Atlas Research Network
Nature 489 (7417), 519, 2012
36852012
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
KA Hoadley, C Yau, DM Wolf, AD Cherniack, D Tamborero, S Ng, ...
Cell 158 (4), 929-944, 2014
15422014
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
JD Campbell, A Alexandrov, J Kim, J Wala, AH Berger, CS Pedamallu, ...
Nature genetics 48 (6), 607-616, 2016
11452016
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, ...
Cancer cell 3 (2), 185-197, 2003
10812003
An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor …
LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ...
Clinical cancer research 19 (1), 279-290, 2013
10192013
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ...
Nature communications 5 (1), 5241, 2014
9412014
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ...
Nature Reviews Cancer 19 (5), 289-297, 2019
8772019
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
E Collisson, J Campbell, A Brooks, A Berger, W Lee, J Chmielecki, D Beer, ...
Nature 511 (7511), 543-550, 2014
8342014
Comprehensive and integrated genomic characterization of adult soft tissue sarcomas
AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ...
Cell 171 (4), 950-965, 2017
8312017
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
7972015
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer
T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ...
Cancer discovery 9 (5), 646-661, 2019
6482019
Small cell lung cancer: where do we go from here?
LA Byers, CM Rudin
Cancer 121 (5), 664-672, 2015
6372015
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ...
Journal of the National Cancer Institute 104 (3), 228-239, 2012
5652012
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ...
Cancer cell 39 (3), 346-360. e7, 2021
5632021
A pan-cancer proteomic perspective on The Cancer Genome Atlas
R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ...
Nature communications 5 (1), 3887, 2014
5562014
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
LA Byers, J Wang, MB Nilsson, J Fujimoto, P Saintigny, J Yordy, U Giri, ...
Cancer discovery 2 (9), 798-811, 2012
5322012
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
CM Rudin, MC Pietanza, TM Bauer, N Ready, D Morgensztern, ...
The Lancet Oncology 18 (1), 42-51, 2017
5072017
Integrative molecular characterization of malignant pleural mesothelioma
J Hmeljak, F Sanchez-Vega, KA Hoadley, J Shih, C Stewart, D Heiman, ...
Cancer discovery 8 (12), 1548-1565, 2018
5062018
系统目前无法执行此操作,请稍后再试。
文章 1–20